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(54) METHOD FOR OBTAINING CINATRINS C3 AND C1
(57) The present invention relates to a process for
obtaining cinatrins C1 and C3 and derivatives thereof
which comprises the hydroxylation of a compound of for-
mula (III). The invention also relates to the intermediates
of said synthesis and to their use for obtaining cinatrins
C1 and C3 and derivatives thereof.
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Description
Field of the Invention
[0001] The present invention relates to processes for the synthesis of cinatrins C1 and C3 and to intermediates of said
synthesis. It also relates to the use of said intermediates in the synthesis of cinatrins C1 and C3.
Background of the Invention
[0002] Cinatrins C3 ((3S,4S,5R)-3,4-dihydroxy-3-dodecyl-4,5-dicarboxytetrahydro-2-furanone) and C1 ((3S,4S,5R)-
3,4-dihydroxy-5-dodecyl-4,5-dicarboxytetrahydro-2-furanone) belong to the family of Cinatrins.
[0003] They were isolated in the year 1992 from the fungus Circinotrichum falcatisporum Pirozynsky (RF-641), isolated
from living leaves of the India rubber tree (Ficus elastica). The structural elucidation of Cinatrins C3 and C1 was carried
out by Dr. Itazaki’s group in 1992 [Itazaki, H.; Nagashima, K.; Kawamura, Y.; Matsumoto, K.; Nakai, H.; Terui, Y. J.
Antibiot. 1992, 45, 38-49.]. They also synthesized the dimethyl esters of cinatrins C1 and C3 from the natural compounds
extracted from the fungus. However, the assignment of the absolute configuration performed by these authors is incorrect,
and in the case of the dimethylated derivative of cinatrin C3 the following configuration was proposed:
[0004] Said configuration was reviewed and corrected by Prof. Evans’s group in 1997 [Evans, D. A.; Trotter, B. W.;
Barrow, J. C. Tetrahedron 1997, 53, 8779-8794.], demonstrating that it corresponds to the enantiomer configuration
proposed by Dr. Itazaki shown above.
[0005] Cinatrins C1 and C3 inhibit the action of the Phospholipase A2 (PLA2) enzyme and therefore have anti-inflam-
matory activity (Farooqui, A. A.; Litski, M. L.; Farooqui, T.; Horrocks, L. Brain Res. Bull. 1999, 49, 139-153; Piñón, P.;
Kaski, J. C. Rev. Esp. Cardiol. 2006, 59, 247-258).
[0006] Two enantioselective syntheses of Cinatrins C3 and C1 have been described in the literature to date. Evans,
D. A.; Trotter, B. W.; Barrow, J. C. Tetrahedron 1997, 53, 8779-8794 describes the first synthesis of these compounds.
The key step in said synthesis consists of the stereoselective titanium-mediated aldol reaction of a tartrate-derived
silylketene acetal, generated from (R,R)-tartaric acid di-tert-butyl ester, and an achiral α-keto ester, prepared from
myristic acid benzyl ester. This synthesis is convergent, it comprises 5 steps and provides an overall yield of 24% for
Cinatrin C3 and 31% for Cinatrin C1. However, the materials used are expensive and use various types of protecting
groups.
[0007] Cuzzupe, A. N.; Di Florio, R.; White, J. M.; Rizzacasa, M. A. Org. Biomol. Chem. 2003, 1, 3572-3577 describes
the second synthesis described to date for Cinatrins C3 and C1. The key step comprises the chelation-controlled addition
of an organometallic reagent to an α-hydroxyketone in the presence of an ester, whereby the C4 quaternary stereogenic
center of Cinatrin C3 is generated. From the hydrolysis of the dimethyl ester of Cinatrin C1 with sodium hydroxide, a
mixture of Cinatrins C3 and C1 in a 1:1 ratio is obtained. The synthesis is linear, it comprises 18 steps and has an overall
yield of 0.95%.
[0008] EP 0 405 864A2, US 5,120,647 and US 5,099,034 also describe obtaining cinatrins by means of isolation from
the culture of Circinotricum falcatisporum RF-641, the subsequent hydrolysis thereof with sodium hydroxide to form the
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seco acid and esterification of the cinatrins to form their dimethyl esters by means of reaction with diazomethane.
[0009] It is therefore necessary to provide an improved synthesis of cinatrins C1 and C3 in terms of efficiency, yield
and cost.
Brief Description of the Drawings
[0010]
Figure 1 shows a retrosynthetic scheme of the sequence leading to the compounds of formula (Ia) and (Ib).
Summary of the Invention
[0011] It has now been found that by following the synthetic sequence of the invention it is possible to obtain compounds
of formula (Ia) and (Ib),including cinatrins C1 and C3, in a reduced number of steps and with a high yield. Said process
has been made possible by means of using the new compounds of formula (II), (III), (V), (VI), (VII), (X), (XI) and (XIII).
[0012] Therefore, a first aspect of the present invention relates to a process for the synthesis of a compound of formula
(II), an intermediate in the synthesis of the compounds of formula (Ia) and (Ib), including cinatrins C1 and C3, their
stereoisomers, or mixtures thereof, from a compound of formula (III).
[0013] An additional aspect relates to the compounds of formula (III), an intermediate of the synthesis of the compounds
of formula (Ia) and (Ib), their stereoisomers, or mixtures thereof, and to processes for obtaining them.
[0014] Other aspects of the present invention relate to compounds of formula (V), (VI), (VII), (X), (XI) and (XIII),
intermediates in the synthesis of the compounds of formula (Ia) and (Ib), their stereoisomers, or mixtures thereof.
[0015] Another additional aspect relates to a process for obtaining the compounds of formula (Ia) and (Ib), their
stereoisomers, or mixtures thereof, from a compound of formula (III).
[0016] Another additional aspect relates to a process for obtaining a compound of formula (Ia), its stereoisomers, or
mixtures thereof, from a compound of formula (III).
[0017] Another additional aspect is aimed at a compound of formula (II) and to its use in the synthesis of the compounds
of formula (Ia) or (Ib), their stereoisomers, or mixtures thereof.
[0018] An additional aspect relates to the use of at least one compound of formula (III), (V), (VI), (VII), (X), (XI) and
(XIII) for the synthesis of cinatrins C1 and C3, their stereoisomers, especially enantiomers, or mixtures thereof, as well
as mixtures of cinatrins C1 and C3 or mixtures of their stereoisomers, especially enantiomers.
Detailed Description of the Invention
Synthesis of cinatrins C1 and C3
[0019] According to a first aspect, the present invention is aimed at a process for obtaining a compound of formula
(II), an immediate precursor of cinatrins C1 and C3,
wherein
R2 is a C10-C15 alkyl group; and
R3 and R5 are independently selected from a substituted or unsubstituted C1-C20 alkyl group;
its stereoisomers, or mixtures thereof;
which process comprises dihydroxylating the double bond of a compound of formula (III)
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(the numbers next to each carbon indicate the numbering of the carbon atoms)
wherein
R2, R3 and R5 are as defined above; and
R1 is selected from a substituted or unsubstituted C1-C20 alkyl group.
[0020] Therefore, the process of the invention for obtaining the compounds of formula (II) first comprises a dihydrox-
ylation of the carbon-carbon double bond of the compound of formula (III), followed by an intramolecular cyclization
giving rise to the compound of formula (II). The stereochemistry of the dihydroxylation is directed by the hydroxyl in C3
of the compound of formula (III), therefore, depending on the stereochemistry in this carbon ((R) or (S)), different ster-
eoisomers of the compounds of formula (Ia) and (Ib) can then be obtained. In other words, the stereoselective dihydrox-
ylation and the subsequent cyclization are achieved in a single step. In any case, it is possible to invert the configuration
of said hydroxyl by means of a Mitsunobu type reaction (for the specific case of inverting configuration of tertiary alcohols
see Shi, Y. -J.; Hughes, D.L.; McNamara, J.M. Tetrahedron Lett. 2003, 44, 3609-3611; or Mukaiyama, T.; Shintou, T.;
Fukumto, K. J. Am. Chem. Soc. 2003, 125, 10538-10539). Alternatively, if the compound of formula (III) is in racemic
form, it will be possible to obtain the compounds of formula (Ia) and (Ib) in racemic form, being able to be used as such
or separated into each of their enantiomers according to the methods which are common general knowledge.
[0021] According to a preferred embodiment, the compound of formula (III) is a compound of formula (IIIa), or its
enantiomers
wherein R1, R2, R3 and R5 are as defined above;
and the compound of formula (II) obtained is a compound of formula (IIa), or its enantiomers
wherein R2, R3 and R5 are as defined above.
[0022] The dihydroxylation reaction can be performed under conditions known by the skilled person, as described in
Smith, M. B.; March, J. March’s Advanced Organic Chemistry; John Wiley & Sons: New York, 2001. pp.: 1048-1051.
According to a preferred embodiment, the dihydroxylation is performed in the presence of osmium tetroxide/N-methyl-
morpholine-N-oxide or potassium permanganate.
[0023] As observed in Figure 1, the preparation of the compound of formula (III) can be carried out by means of two
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alternative routes. Thus, according to a preferred embodiment, the compound of formula (III) is prepared by
(a) reacting a compound of formula (V)
wherein
R1, R2 and R3 are as defined above;
in the presence of a compound of formula (XII)
wherein
R5 is as defined above;
or
(b) oxidizing with a peroxide or with sodium periodate a compound of formula (VI)
wherein
R1, R2, R3 and R5 are as defined above; and
R6 is selected from the group formed by C1-C3 alkyl and phenyl.
[0024] According to option a) the compound of formula (XII), a stabilized ylide, reacts with the compound of formula
(V) to yield the compound of formula (III). Said stabilized ylide can be prepared according to known methods (Villa, M.
J.; Warren, S. J. Chem. Soc. P. T 1 1994, 12, 1569-1572) or be commercially purchased. According to a preferred
embodiment, said ylide is [(methoxycarbonyl)methylene]triphenylphosphorane. Following option b), the hydroxyl is in-
troduced in C3 of the compound of formula (III) according to conditions known in the state of the art, for example with
a peroxide, preferably hydrogen peroxide, or with sodium permanganate. Said introduction involves the sequence: (i)
oxidation of the selenium atom, (ii) stereospecific 1,3-sigmatropic rearrangement, and (iii) release of the hydroxyl. For
example, see Nishiyama, H.; Narimatsu, S.; Itoh, K. Tetrahedron Lett. 1981, 22, 5289-5292; or Werkhoven, T.M.; Nisper,
R.; Lugtenburg, J. J. Eur. J. Org. Chem. 1999, 11, 2909-2914.
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[0025] According to a preferred embodiment, and following synthetic route b), the compound of formula (VI) is prepared
by reacting a compound of formula (XIII)
wherein
R1, R2, R3 and R6 are as defined above;
in the presence of a base and a phosphonate of formula (XIV)
wherein
R5 is as defined above and R7 is a C1-C3 alkyl group.
[0026] According to a preferred embodiment, said base is selected from the group formed by sodium hydride, lithium
di-iso-propylamine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), preferably
sodium hydride. The phosphonate of formula (XIV) used is preferably methyl (dimethoxyphosphoryl)acetate.
[0027] According to a preferred embodiment, the compound of formula (XIII) is prepared by reacting in the presence
of a base a compound of formula (VII)
wherein
R1, R2 and R3 are as defined above;
with a compound of formula (XV)
R6SeX (XV)
wherein
R6 is as defined above, and
X is a halogen selected from C1 and Br.
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[0028] Said base is preferably selected from the group formed by sodium hydride, a secondary amine such as mor-
pholine, diethylamine, N-phthalimide or bis(trimethylsilyl)amides of alkali metals such as lithium (LiHMDS), sodium
(NaHMDS) or potassium (KHMDS), preferably sodium hydride or morpholine.
[0029] Phenylselenyl bromide (PhSeBr) is preferably used as compound of formula (XV).
[0030] Said reaction can be carried out following methods known in the state of the art. For example, it is possible to
add the compound of formula (XV) on a solution of sodium enolate generated from the compound of formula (VII) (see
Smith, M. B.; March, J. March’s Advanced Organic Chemistry; John Wiley&Sons: New York, 2001. pp.: 548-556.).
Alternatively, it is possible to prepare a solution comprising an amine, for example morpholine, and the compound of
formula (XV), and then add the compound of formula (VII) on said solution (see Boivin, S.; Outurquin, F.; Paulmier, C.
Tetrahedron 1997, 53, 16767-16782.). According to a preferred embodiment, the base used is a chiral secondary amine,
giving rise to an enantiomerically pure or enantiomerically enriched compound of formula (XIII). Therefore, known chiral
secondary amines such as proline (see for example Vignola, N.; List, B. J. Am. Chem. Soc. 2004, 126, 450-451) allow
obtaining the two enantiomers of the compounds of formula (XIII) or enantiomerically enriched mixtures thereof, and
therefore the compounds of formula (VI), (III) and (II), and enantiomerically enriched or enantiomerically pure cinatrins
C1 and C3.
[0031] Therefore, according to route b), the compounds of formula (VI) can be prepared following a synthetic route
which comprises
(i) reacting a compound of formula (VII) with a compound of formula (XV) to obtain a compound of formula (XIII); and
(ii) reacting said compound of formula (XIII), in the presence of a base, with a phosphonate of formula (XIV).
[0032] Returning to route a) for obtaining the compounds of formula general (III), according to a preferred embodiment,
the compound of formula (V) is prepared by reacting a compound capable of generating fluoride ions with a compound
of formula (XI)
wherein
R1, R2 and R3 are as defined above, and
R4 is a trialkylsilyl group.
[0033] As can be observed, the epoxide group in the compound of formula (XI) opens regioselectively to form a
compound of formula (V). General regioselective opening methods are known in the art, such as those described in
Pujol, B.; Sabatier, R.; Driguez, P. A.; Doutheau, A. Tetrahedron Lett. 1992, 33, 1447-1450.
[0034] This opening is performed with a compound capable of generating fluoride ions. Preferably, the hydrofluoric
acid-pyridine system, hydrofluoric acid in aqueous solution or a trihydrogen fluoride of formula NR3·3HF, wherein R is
independently selected from the group consisting of hydrogen and C1-C8 alkyl, is used; more preferably, the compound
used is triethylamine tris-hydrofluoride (Et3N·3HF).
[0035] Each of the two enantiomers of the compounds of formula (V) can be obtained by means of the regiospecific
opening of the suitable enantiomer of the compound of formula (XI), when the latter is prepared by means of asymmetric
epoxidation. Alternatively, if the compound of formula (XI) is in racemic form, the compound of formula (V) will also be
obtained in its racemic form, being able to be used as such or separated into each of its enantiomers according to the
methods which are common general knowledge.
[0036] According to a preferred embodiment, the compound of formula (XI) is obtained by reacting an epoxidizing
agent with a compound of formula (X)
EP 2 287 157 A1
8
5
10
15
20
25
30
35
40
45
50
55
wherein
R1, R2, R3 and R4 are as defined above.
[0037] Non-limiting examples of conditions in which this transformation can be carried out can be found in, for example,
a) Pujol, B.; Sabatier, R.; Driguez, P. A.; Doutheau, A. Tetrahedron Lett. 1992, 33, 1447-1450; or b) Lowinger, T. B.;
Chu, J.; Spence, P. L. Tetrahedron Lett. 1995, 36, 8383-8386. It is also possible to find a general explanation about
these reactions in the following references: (a) Smith, M. B.; March, J. March’s Advanced Organic Chemistry; John Wiley
& Sons: New York, 2001, pp. 1051-1054; (b) Davis, F. A.; Sheppard, A. C. J. Org. Chem. 1987, 52, 954-955; or (c)
Dayan, S.; Bareket, Y.; Rozen, S. Tetrahedron 1999, 55, 3657-3664. According to a preferred embodiment, said epox-
idizing agent is selected from the group consisting of m-CPBA, 2-sulfonyloxaziridines and the HOF·CH3CN complex;
more preferably m-CPBA.
[0038] As mentioned above, it is possible to perform the epoxidation of the compound of formula (X) in an asymmetric
manner in order to obtain the compound of formula (XI) with an enantiomeric excess or in an enantiomerically pure
manner, opening the route to compounds of formula (II), and therefore also to the compounds of formula (Ia) and (Ib),
with an enantiomeric excess or in an enantiomerically pure manner.
[0039] Therefore, the present invention also contemplates the methods for the asymmetric epoxidation of the com-
pounds of formula (X) such as those described in the art by means of using chiral auxiliaries as described in Walkup,
R. D.; Obeyesekere, N. U. J. Org. Chem. 1988, 53, 920-923; or by means of using chiral catalysts as described in Zhu,
Y.; Tu, Y.; Yu, H.; Shi, Y. Tetrahedron Lett. 1998, 39, 7819-7822.
[0040] According to a preferred embodiment, the compound of formula (X) is prepared by reacting a compound of
formula (VII)
wherein
R1, R2 and R3 are as defined above;
with a trialkylsilyl halide or with a trialkylsilyl triflate in the presence of a base.
[0041] Non-limiting examples of conditions under which this transformation can be carried out can be found in, for
example, Dalla, V.; Catteau, J. P. Tetrahedron 1999, 55, 6497-6510, and the trialkylsilyl groups which can be used in
this reaction, as well as reagents suitable for their introduction, are known for the person skilled in the art (for example
see Greene, T. W.; Wuts, P. G. M. Greene’s Protective Groups in Organic Synthesis; John Wiley & Sons: Hoboken,
2007. pp.: 189-196.
[0042] According to a preferred embodiment, the trialkylsilyl group is selected from the group formed by trimethylsilyl,
triethylsilyl, tri-iso-propylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylthexylsilyl, tert-butyldimethylsilyl and
tert-butyldiphenylsilyl; and the preferred halides are selected from chlorine and iodine.
[0043] The trialkylsilyl group is preferably tert-butyldimethylsilyl; and the preferred trialkylsilyl triflate is tert-butyldimeth-
ylsilyl trifluoromethanesulfonate.
[0044] The reaction of the compounds of formula (VII) can give rise to two stereoisomers of the compounds of formula
(X), according to the stereochemistry of the double bond in C2-C3 ((E) or (Z)). For the purposes of the present invention,
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it is irrelevant which of the two stereoisomers is formed. As has been mentioned above, it will be possible to invert the
stereochemistry of the hydroxyl in the C3 position (for example, in compounds of (III) or (V)) by means of the Mitsunobu
reaction, which allows obtaining any of the enantiomers of the compounds of formula (II), and therefore different stere-
oisomers of compounds of formula (Ia) and (Ib).
[0045] Therefore, according to route a), the compounds of formula (V) can be prepared following the synthetic route
which comprises:
(i) reacting said compound of formula (VII) with a trialkylsilyl halide or with a trialkylsilyl triflate in the presence of a
base to obtain a compound of formula (X);
(ii) reacting said compound of formula (X) with an epoxidizing agent to obtain a compound of formula (XI); and
(iii) reacting said compound of formula (XI) with a compound capable of generating fluoride ions.
[0046] As can be seen, in both routes a) and b), the common intermediate is a compound of formula (VII). According
to a preferred embodiment, the compound of formula (VII) is prepared by reacting in the presence of a base a compound
of formula (VIII)
wherein
R1 and R2 are as defined above;
with an oxalic acid diester of formula (IX)
wherein
R3 is as defined above.
[0047] According to a preferred embodiment, said base is an inorganic base. Non-limiting examples of conditions
under which this transformation can be carried out can be found in, for example, Dubowchik, G. M.; Padilla, L.; Edinger,
K.; Firestone, R. A. J. Org. Chem. 1996, 61, 4676-4684. According to a preferred embodiment, said base is sodium
hydride.
[0048] As mentioned above, the compounds of formula (Ia) and (Ib) can be prepared from the compounds of formula
(III) by means of dihydroxylation followed by hydrolysis of the compound of formula (II) obtained in the presence of a
base and subsequent acidification. Therefore, an additional aspect of the invention relates to a process for preparing
compounds of formula (Ia) and (Ib), their stereoisomers, or mixtures thereof, or mixtures of the compounds of formula
(Ia) and (Ib) or mixtures of their stereoisomers, which comprises
(i) dihydroxylating the double bond of a compound of formula (III) to obtain a compound of formula (II), its stereoi-
somers, or mixtures thereof;
(ii) hydrolyzing said compound of formula (II) in the presence of an alkali or alkaline earth metal hydroxide, or of an
alkali or alkaline earth metal carbonate; and
(iii) acidifying the reaction medium;
wherein the R3 and R5 groups can be hydrolyzed under the basic conditions of step (ii).
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[0049] As has been described throughout the present document, the synthesis of the compounds of formula (II), and
therefore also of the compounds of formula (Ia) and (Ib), can be chiral by means of the synthesis of enantiomerically
pure or enantiomerically enriched intermediates.
[0050] Therefore, a preferred embodiment of the present invention comprises the preparation of compounds of formula
(Ia’) and (Ib’), or their enantiomers
wherein
R2 is as defined above;
from compounds of formula (IIIa) and (IIa), or their enantiomers.
[0051] As can be observed, the hydrolysis in basic medium and subsequent acidification (steps (ii) and (iii)) of the
compounds of formula (II) involves the hydrolysis of the carboxy ester groups of which R3 and R5 form part to give rise
to the corresponding carboxy acids. Therefore, in order to carry out the transformation indicated above it is necessary
for the carboxy esters of which R3 and R5 form part to be labile in basic medium. Without wishing to be bound by theory,
it seems that the step (ii) of the process for preparing compounds of formula (Ia) and/or (Ib) involves the formation of a
triacid, the lactonization of the hydroxyl of the C2 position of which with the carboxy acid group of the C4 position (see
route A in scheme 2) would generate a compound of formula (Ia). In addition, it seems that the acidic medium used in
step (iii) must allow the formation of a tertiary carbocation, generated by means of the loss of the OH group of the C4
position of the triester provided by the acidic medium used (see route B in scheme 2). The subsequent cyclization of
the carboxy acid group of the C2 position with said carbocation in the C4 position would generate a compound of formula
(Ib).
[0052] Suitable bases for the hydrolysis of carboxylic esters and for opening the ring in the compounds of formula (II)
(step (i)) are known by the skilled person, such as lithium hydroxide, sodium hydroxide, potassium hydroxide, potassium
carbonate, cesium carbonate, barium hydroxide.
[0053] Any protic acid will allow closing the cycle to form cinatrins C1 and C3 (step (ii)), the acid used is preferably
hydrochloric acid.
[0054] Similar conditions for this reaction can be found in Cuzzupe, A. N.; Di Florio, R.; White, J. M.; Rizzacasa, M.
A. Org. Biomol. Chem. 2003, 1, 3572-3577.
[0055] Said process can give rise to mixtures of the corresponding compounds of formula (Ia) and (Ib), which can be
separated into the corresponding essentially pure compounds by means of methods which are common general knowl-
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edge (for example, chromatographic column or recrystallization).
[0056] Alternatively, it is possible to directly obtain the compounds of formula (Ia) from compounds of formula (II) and
(III) without needing to form compounds of formula (Ib). This can be achieved by transforming the carboxy ester groups
of which R3 and R5 form part into carboxy acid groups under conditions which do not give rise to the opening of the
lactone and therefore under conditions which do not allow the formation of the aforementioned triacid (see Scheme 2),
the origin of the formation of both compounds of formula (Ia) and of formula (Ib). Consequently, an additional aspect of
the present invention is a process for preparing a compound of formula (Ia)
wherein R2 is a C10-C15 alkyl group; its stereoisomers, or mixtures thereof, which comprises (i) dihydroxylating the
double bond of a compound of formula (III), as defined above, to obtain a compound of formula (II)
wherein R2, R3 and R5 are as defined above; its stereoisomers, or mixtures thereof; and (ii) transforming under non-
basic conditions the carboxy ester groups of the lactone ring of the compound of formula (II) to obtain the corresponding
carboxy acid groups.
[0057] Conditions under which it is possible to perform the transformation of step (ii) are generally those in which it is
possible to transform the carboxy ester groups of which R3 and R5 form part into carboxy acid groups under conditions
which do not given rise to the opening of the lactone. Carboxy ester groups which can be transformed into carboxy acid
groups under non-basic conditions (for example, by hydrogenation or in acidic medium) are known for the person skilled
in the art. Non-limiting examples are esters derived from p-methoxybenzyl, 1-phenyl-ethyl, or trityl.
[0058] According to a preferred embodiment, R3 and R5 are benzyl groups (-(CH)2-phenyl). The hydrogenation of a
compound of formula (II) wherein R3 and R5 are benzyl only provides a compound of formula (Ia), without significant
amounts of compounds of formula (Ib) being obtained. For similar conditions, see for example the transformation of
compound 20 into compound 14 in Evans, D. A.; Trotter, B. W.; Barrow, J. C. Tetrahedron 1997, 53, 8779-8794, incor-
porated in its entirety to the description of the present invention. According to another preferred embodiment, it is possible
for the R3 and R5 groups to be labile in acidic medium. The acidification of the reaction medium removes said R3 and
R5 groups to form the corresponding carboxy acids, without opening the lactone of the compound of formula (II), therefore
providing a compound of formula (Ia), without the formation of significant amounts of a compound of formula (Ib) being
observed. For example, if R3 and R5 are t-butyl, it is possible to obtain the corresponding carboxy acids in acidic medium
(for example, with trifluoroacetic acid) without the ring being opened. For example, see the transformation of compound
19 into compound 13 in Evans, D. A.; Trotter, B. W.; Barrow, J. C. Tetrahedron 1997, 53, 8779-8794.
[0059] According to a preferred embodiment, R2 is n-dodecyl. According to another preferred embodiment, R1 is a
C1-C3 alkyl, preferably methyl. According to another preferred embodiment, R3 is a C1-C3 alkyl, preferably methyl.
According to another preferred embodiment, R5 is a C1-C3 alkyl, preferably methyl.
Intermediates of the process of the invention and use thereof
[0060] In view of what has been seen up until now, the compounds of formula (II) are intermediates in the synthesis
of the present invention. Therefore, an additional aspect of the invention relates to a compound of formula (II)
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wherein
R2 is selected from a C10-C15 alkyl group;
R3 and R5 are independently selected from a substituted or unsubstituted C1-C20 alkyl group;
its stereoisomers, especially enantiomers, or mixtures thereof;
with the proviso that the compound of formula (II) is not
[0061] The use of the compounds of formula (II) defined above for the synthesis of compounds of formula (Ia) or (Ib),
their stereoisomers, or mixtures thereof, as well as mixtures of compounds of formula (Ia) and (Ib) or mixtures of their
stereoisomers, is also an aspect of the present invention.
[0062] Other aspects of the present invention relate to compounds of formula (III), (V), (VI), (VII), (X), (XI) and (XIII),
intermediates in the synthesis of the invention, their stereoisomers, or mixtures thereof.
[0063] According to a preferred embodiment, R2 in the compounds of formula (III), (V), (VI), (VII), (X), (XI) and (XIII)
is n-dodecyl. According to another preferred embodiment, R1 is methyl. According to another preferred embodiment,
R3 is methyl. According to another preferred embodiment, R5 is methyl.
[0064] The use of the compounds of formula (III), (V), (VI), (VII), (X), (XI) and (XIII) for the synthesis of compounds of
formula (Ia) or (Ib), their stereoisomers, or mixtures thereof, as well as mixtures of compounds of formula (Ia) and (Ib)
or mixtures of their stereoisomers, is also an aspect of the present invention.
Definitions
[0065] For the purpose of facilitating the understanding of the present invention, the meanings of several terms and
expressions as they are used in the context of the invention are included herein.
[0066] "Alkyl" refers to a radical with a linear or branched hydrocarbon chain which consists of carbon and hydrogen
atoms, which does not contain unsaturations and which is attached to the rest of the molecule by means of a single
bond. The number of carbon atoms of the alkyl group is specified in each case. For example, when "C1-C4 alkyl" is
indicated it refers to an alkyl group of one, two, three of four carbon atoms, i.e., methyl, ethyl, propyl, isopropyl or n-
butyl. For example, when "C10-C15 alkyl" is indicated it refers to an alkyl group of ten, eleven, twelve, thirteen, fourteen
or fifteen carbon atoms, such as decyl, undecyl, dodecyl, tridecyl, tetradecyl or pentadecyl.
[0067] "Halide" or "halogen" means-F, -Cl, -Br or -I;
[0068] A "stereoisomer" in the present application refers to compounds formed by the same atoms attached by the
same sequence of bonds but having different three-dimensional structures which are not interchangeable.
[0069] "Enantiomer" is understood as the mirror image of a stereoisomerically pure compound. For the purposes of
the invention, an enantiomer can be considered as a mixture of two enantiomers having an enantiomeric excess greater
than 95%, preferably
[0070] greater than 98%, more preferably greater than 99%, more preferably greater than 99.5%.
[0071] "Bn" means benzyl (-(CH2)-phenyl).
[0072] "Trialkylsilyl" is understood as a radical of formula -Si(R’)(R")R"’, wherein each of R’, R" and R"’ are independ-
ently selected from among a phenyl group and a C1-C6 alkyl group. Non-limiting examples of trialkylsilyl groups can be
trimethylsilyl, triethylsilyl, tri-iso-propylsilyl; dimethylisopropylsilyl, diethylisopropylsilyl, dimethylthexylsilyl, tert-butyld-
imethylsilyl, tert-butyldiphenylsilyl.
[0073] The references of the present document to substituted groups in the compounds of the present invention refer
to the specified moiety which can be substituted in one, two or three available positions with one, two, three suitable
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groups, which are independently selected from the group consisting of cyano; alkanoyl, such as a C1-C6 alkanoyl group,
such as acyl and the like; carboxamido (-(C=O)NH2); trialkylsilyl; carbocyclic aryl having 6 or more carbons, particularly
phenyl or naphthyl and (C1-C3)alkylaryl such as tolyl. As a non-limiting example, "substituted alkyl" includes groups such
as cyanoethyl, acetylmethyl, carboxamidomethyl (-CH2CONH2), 2-trimethylsilylethyl, benzyl, diphenylmethyl.
[0074] "Aryl" refers to a C6-C14 aromatic hydrocarbon radical such as phenyl, naphthyl or anthracyl.
[0075] Unless otherwise indicated, the compounds of the invention also refer to those including compounds which
differ only in the presence of one or more isotopically enriched atoms. For example, the compounds having the present
structures, with the exception of the substitution of a hydrogen with a deuterium or with tritium, or the substitution of a
carbon with a 13C- or 14C-enriched carbon, are within the scope of this invention.
[0076] The following examples illustrate different embodiments of the invention and must not be considered as limiting
the scope thereof.
Examples
General methods and materials
[0077] All the reactions were performed under an argon atmosphere, except those indicated in each case. The solvents
used were distilled and dried under an argon atmosphere. The reagents and solvents used are from the companies
Aldrich, Fluka, Merck, Sigma, Acros, Lancaster, SDS or Scharlau, and were purified by usual processes when necessary.
The purification of the reaction products was performed by column chromatography under pressure (flash chromatog-
raphy), using 60 Merck silica gel (with a 230-400 mesh particle size) as a stationary phase.
[0078] The (fully decoupled) 1H and 13C nuclear magnetic resonance spectra were performed at room temperature
in the solvent indicated in each case (CDCl3 and CD3OD) using the following apparatuses: Varian Gemini-200 (200
MHz), Varian INOVA-300 (300 MHz), Bruker Avance-300 (300 MHz) and Varian INOVA-400 (400 MHz). The values of
the chemical shifts are expressed in parts per million (δ, ppm), using as an internal reference the residual signal of the
solvent: CDCl3, 7.26 ppm (1H-NMR) and 77.0 ppm (13C-NMR); CD3OD, 3.31 ppm (1H-NMR) and 49.0 ppm (13C-NMR).
The 1H-NMR spectra are described indicating the number of protons and the apparent multiplicity of each signal. The
coupling constants (J) are the apparent ones and are expressed in Hz. The following abbreviations have been used: s
(singlet), d (doublet), t (triplet), c (quadruplet), q (quintuplet) and m (multiplet).
[0079] The melting points (m.p.) were measured in a Reichert brand Kofler microscope. The infrared (IR) spectra were
recorded in the Perkin-Elmer spectrophotometer models 681 and FT-IR Spectrum One. The low resolution mass spectra
(LRMS) were recorded: (1) by direct injection of the sample into a Hewlett Packard 5973 MSD spectrophotometer using
the electron impact (EI) ionization technique; or (2) in a Hewlett Packard LCMS 1100 MSD spectrophotometer (an HPLC-
coupled quadrupole analyzer) using the electrospray chemical ionization technique (API-ES) in positive or negative
modes. The elemental analyses (E.A.) were performed with the Perkin-Elmer 240C and Heraus CHN-O-Rapid analyzers.
[0080] Unless otherwise indicated, all the products shown in the examples are racemic (rac).
Example 1
Preparation of methyl rac-(S)-3-(methoxycarbonyl)-2-oxopentadecanoate
[0081]
[0082] MeOH (0.5 ml) was added at 0°C to a suspension ofNaH (1.08 g, 45.3 mmoles) in THF (19.5 ml). The mixture
was stirred until it reached room temperature. Then, methyl myristate (10 g, 41.2 mmoles) and dimethyl oxalate (4.87
g, 41.2 mmoles) were added. The resulting mixture was heated under reflux for 3 hours. After that time, H2O (19 ml)
was added at 0°C and the mixture was neutralized with an aqueous solution of 10% HCl. The phases were separated,
and the aqueous phase was extracted with AcOEt (310 ml). The organic phase was dried with anhydrous Na2SO4,
filtered and the solvent was removed under reduced pressure. The product was purified by a chromatographic column
(hexane/AcOEt, 20:1), obtaining (8.61 g, yield 64%) methyl rac-(S)-3-(methoxycarbonyl)-2-oxopentadecanoate, as a
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transparent oil.
1H-NMR (300 MHz, CDCl3). δ 4.01 (1H, t, J= 6.9 Hz, H-3), 3.88 (3H, s, -OCH3), 3.71 (3H, s, -OCH3), 1.88 (2H, m, H-
4), 1.24 (20H, m, -CH2-), 0.86 (3H, m, -CH3).
Example 2
Preparation of methyl 2-(tert-butyldimethylsilyloxy)-3-(methoxycarbonyl)-2-pentadecenoate
[0083]
[0084] TBDMSOTf (1.84 g, 6.96 mmoles) was added at 0°C to a solution of methyl rac-(S)-3-(methoxycarbonyl)-2-
oxopentadecanoate (1.90 g, 5.80 mmoles) and Et3N (1.17 g, 11.6 mmoles) in CH2Cl2 (48 ml). The mixture was stirred
at room temperature for 24 hours. After that time, the solvent was removed under reduced pressure. The product was
purified by a chromatographic column (hexane/AcOEt, 12:1), obtaining (2.09 g, yield 82%) methyl 2-(tert-butyldimeth-
ylsilyloxy)-3-(methoxycarbonyl)-2-pentadecenoate, as a transparent oil.
IR (NaCl): v 3388, 2943, 2927, 2854, 1738, 1716, 1627, 1432, 1310, 1204, 1129, 1097, 840, 811, 784 cm-1.
1H-NMR (300 MHz, CDCl13). δ 3.79 (3H, s, -OCH3), 3.71 (3H, s, -OCH3), 2.29 (2H, m, -CH2-), 1.32 (20H, m, -CH2-),
0.94 (9H, s, tert-BuSi), 0.87 (3H, m, -CH3), 0.17 (6H, s, (CH3)2Si).
13C-NMR (75 MHz, CDCl3). δ 182.3, 168.6, 165.8, 118.2, 52.2, 51.7, 31.9, 29.6, 29.5, 29.4, 29.3, 28.2, 26.0, 25.4, 22.6,
18.3, 14.1, -4.6.
LRMS(EI): m/z 442(M+, 0), 441(M+-1, 1), 427(3), 411(3), 385(100).
E.A. (C24H46O5Si): Found: C, 65.00, H, 10.50; Calculated: C, 65.11, H, 10.47.
Example 3
Preparation of methyl rac-(2R,3R)-2-(tert-butyldimethylsilyloxy)-2,3-epoxy-3-(methoxycarbonyl)-bentadecanoate
[0085]
m-CPBA (7.77 g, 45.0 mmoles) was added to a solution of methyl 2-(tert-butyldimethylsilyloxy)-3-(methoxycarbonyl)-2-
pentadecenoate (9.96 g, 22.5 mmoles) in CH2Cl2 (129 ml). The mixture was stirred at room temperature for 5 days.
After that time, Celite was added and the solvent was removed under reduced pressure. The product was purified by a
chromatographic column (hexane/AcOEt, 10:1), obtaining (9.96 g, yield 96%) methyl rac-(2R,3R)-2-(tert-butyldimethyl-
silyloxy)-2,3-epoxy-3-(methoxycarbonyl)-pentadecanoate, as a transparent oil.
IR (NaCl): v 3389, 2952, 2928, 2856, 1758, 1462, 1440, 1401, 1362, 1307, 1255, 1199, 1165, 1100, 1004, 843, 785 cm-1.
1H-NMR (300 MHz, CDCl3). δ 3.76 (3H, s, -OCH3), 3.75 (3H, s, -OCH3), 2.07 (1H, m, H-4), 1.78 (1H, m, H-4), 1.46 (2H,
m, H-5), 1.24 (18H, Sbroad, -CH2-), 0.91 (9H, s, tert-BuSi), 0.87 (3H, m, -CH3), 0.20 (3H, s, (CH3)2Si), 0.15 (3H, s, (CH3)2Si).
13C-NMR (75 MHz, CDCl3). δ 168.1, 166.4, 82.0, 68.0, 52.8, 52.4, 31.8, 29.5, 29.5, 29.4, 29.3, 29.3, 28.1, 25.3, 24.4,
22.6, 17.9, 14.0, -4.0, -4.6.
LRMS(EI): m/z 458(M+, 0), 443(2), 427(0), 401(66), 399(9), 341(10), 313(3), 281(2), 233(100).
E.A. (C24H46O6Si): Found: C, 63.00, H, 10.00; Calculated: C, 62.84, H, 10.11.
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Example 4
Preparation of methyl rac-(R)-3-hydroxy-3-(methoxycarbonyl)-2-oxopentadecanoate
[0086]
Et3N·(HF)3 (0.95 g, 5.90 mmoles) was added to a solution of methyl rac-(2R,3R)-2-(tert-butyldimethylsilyloxy)-2,3-epoxy-
3-(methoxycarbonyl)pentadecanoate (9.01 g, 19.66 mmoles) in MeOH (180 ml). The mixture was stirred at room tem-
perature for 2.5 hours. After that time, AcOEt was added, and the mixture was washed with H2O (2  3 ml), dried with
anhydrous Na2SO4, filtered and the solvent was removed under reduced pressure. The product, methyl rac-(R)-3-
hydroxy-3-(methoxycarbonyl)-2-oxopentadecanoate, was used in the following step without purifying.
IR (NaCl): v 3473, 2955, 2925, 2854, 1740, 1438, 1259, 1138, 1074 cm-1.
1H-NMR (300 MHz, CDCl3). δ 3.87 (3H, s, -OCH3), 3.84 (3H, s, -OCH3), 1.95 (2H, m, H-4), 1.24 (20H, Sbroad, -CH2-),
0.87 (3H, t, J= 6.5 Hz, -CH3).
13C-NMR (75 MHz, CDCl3). δ 188.5, 170.7, 162.0, 80.5, 53.6, 53.0, 33.9, 31.8, 29.5, 29.5, 29.5, 29.4, 29.2, 22.6, 22.4, 14.0.
LRMS(EI): m/z 345(M++1,0), 313(1), 286(0), 257(14), 225(0), 197(100).
Example 5
Preparation of methyl rac-(2Z,4R)-4-hydroxy-3,4-bis(methoxycarbonyl)-2-hexadecenoate
[0087]
[(Methoxycarbonyl)methylene]triphenylphosphorane (16.43 g, 49.12 mmoles) was added to a solution of methyl
rac-(R)-3-hydroxy-3-(methoxycarbonyl)-2-oxopentadecanoate (6.77 g, 19.65 mmoles), obtained previously, in CH2Cl2
(186 ml). The mixture was stirred at room temperature for 48 hours. After that time, Celite was added and the solvent
was removed under reduced pressure. The product was purified by a chromatographic column (hexane/AcOEt, 7:1),
obtaining (7.60 g, yield 97%) methyl rac-(2Z,4R)-4-hydroxy-3,4-bis(methoxycarbonyl)-2-hexadecenoate a s a colorless
oil.
IR (NaCl): v 3494, 2925, 2854, 1733, 1646, 1436, 1349, 1256, 1199, 1168, 1019 cm-1.
1H-NMR (300 MHz, CDCl3). δ 6.26 (1H, s, H-2), 3.80 (3H, s, -OCH3), 3.80 (3H, s, - OCH3), 3.71 (3H, s, -OCH3), 3.67
(1H, s, -OH), 1.91 (2H, m, -CH2-), 2.43 (2H, m, - CH2-), 1.22 (18H, m, -CH2-), 0.85 (3H, t, J = 6.8 Hz, -CH3).
13C-NMR (75 MHz, CDCl3). δ 173.0, 166.8, 164.9, 151.0, 120.3, 77.7, 53.6, 52.4, 52.0, 37.5, 31.8, 31.5, 29.5, 29.5,
29.4, 29.3, 29.3, 29.2, 23.1, 22.6, 14.0.
LRMS (EI): m/z 401(M++1,3), 383(1), 369(8), 341(28), 309(100), 249(18), 197(18).
E.A. (C21H36O7): Found: C, 63.00, H, 9.00; Calculated: C, 62.98, H, 9.06.
Example 6
Preparation of [(methoxycarbonyl)methylene]-triphenylphosphorane
[0088]
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Methyl bromoacetate (5.3 g 34.6 mmoles, 1 eq.) was added to a solution of PPh3 (9.52 g, 36.3 mmoles, 1.05 eq.) in
toluene (20 ml). The mixture was stirred at room temperature for 24 hours. A suspension was gradually formed, which
was filtered under vacuum and washed with toluene (3  10 ml). The product, [(methoxycarbonyl)methyl]triphenylphos-
phonium bromide, was used in the following step without purifying.
1H-NMR (200MHz, CDCl3). δ 8.00-7.60 (15H, m, Ar-H), 5.62 (1H, d, JP,H = 15.5 Hz, H-1), 3.61 (3H, s, -OCH3).
[0089] An aqueous solution of 1.15 N NaOH (60 ml) was added at room temperature to a solution of [(methoxycarbonyl)
methyl]triphenylphosphonium bromide (14.3 g, 34.6 mmoles, 1 eq.), obtained previously, in CH2Cl2 (90 ml). The resulting
mixture was stirred vigorously at room temperature for 2 hours. After that time, the phases were separated. The aqueous
phase was extracted with CH2Cl2 (3  10 ml). The organic phase was dried with anhydrous MgSO4, filtered and the
solvent was removed under reduced pressure, obtaining (10.5 g, yield 90%) [(methoxycarbonyl)methylene]-triphenyl-
phosphorane as a white solid.
1H-NMR (200MHz, CDCl3). δ 7.61 (15H, m, Ar-H), 5.62 (1H, m, H-1), 3.50 (3H, s, - OCH3).
Example 7
Preparation of methyl rac-(R)-3-(phenylselenyl)-3-(methoxycarbonyl)-2-oxopentadecanoate
Method A
[0090]
[0091] A solution of methyl rac-(S)-3-(methoxycarbonyl)-2-oxopentadecanoate (6 g, 18.26 mmoles) in THF (17 ml)
was added to a suspension of NaH (0.482 g, 20.09 mmoles) in THF (34 ml). The mixture was stirred at room temperature
until H2 was no longer evolved (10 minutes). Then, the mixture was cooled at 0°C and a solution of BrSePh (4.74 g,
20.09 mmoles) in THF (17 ml) was added. The resulting mixture was stirred at room temperature for 24 hours. After that
time, H2O (50 ml) was added. The phases were separated, and the aqueous phase was extracted with AcOEt (3  30
ml). The organic phase was dried with anhydrous Na2SO4, filtered and the solvent was removed under reduced pressure.
The product was purified by a chromatographic column (hexane/AcOEt, 10:1), obtaining (5.63 g, yield 65%) methyl
rac-(R)-3-(phenylselenyl)-3-(methoxycarbonyl)-2-oxopentadecanoate, as a brown oil.
Method B
[0092]
Morpholine (0.221 g, 2.54 mmoles) was slowly added at room temperature to a solution of BrSePh (0.300 g, 1.27 mmoles)
in CH2Cl2 (12 ml). The resulting mixture was stirred at room temperature for 15 minutes. Then, a solution of methyl rac-
(S)-3-(methoxycarbonyl)-2-oxopentadecanoate (0.417 g, 1.27 mmoles) in CH2Cl2 (2 ml) was added. The resulting mixture
was stirred at room temperature for 24 hours, during which time a solid in suspension gradually appeared. After that
time, the solid was filtered under vacuum over Celite, and the solvent was removed under reduced pressure. The product
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was purified by a chromatographic column (hexane/AcOEt, 10:1), obtaining (0.368 g, yield 60%) methyl rac-(R)-3-(phe-
nylselenyl)-3-(methoxycarbonyl)-2-oxopentadecanoate, as a brown oil.
IR (NaCl): v 3057, 2925, 2854, 1736, 1713, 1577, 1438, 1299, 1232, 1129, 1064, 1020, 999, 743, 692 cm-1.
1H-NMR (200 MHz, CDCl3). δ 7.36 (5H, m, Ar-H), 3.95 (3H, s, -OCH3), 3.81 (3H, s, - OCH3), 1.70 (2H, m, -CH2-),
1.43-1.24 (20H, m, -CH2-), 0.88 (3H, m, -CH3).
13C-NMR (50 MHz, CDCl3). δ 179.6, 168.3, 161.2, 137.8, 130.1, 129.3, 129.0, 124.6, 64.9, 53.3, 53.2, 31.6, 30.7, 29.2,
29.0, 27.0, 25.4, 24.6, 24.3, 22.5, 22.2, 20.8, 14.0.
LRMS(EI): m/z 484(M++1,96), 426(3), 397(100), 365(60), 337(50), 269(14), 235(12), 157(55).
E.A. (C24H36O5Se): Found: C, 59.70, H, 7.30; Calculated: C, 59.62, H, 7.50.
Example 8
Reaction of methyl rac-(R)-3-(phenylselenyl)-3-(methoxycarbonyl)-2-oxopentadecanoate with methyl (dimethoxyphos-
phoryl)acetate
[0093]
[0094] A solution of methyl (dimethoxyphosphoryl)acetate (2.33 g, 12.8 mmoles) in THF (8 ml) was added to a sus-
pension ofNaH (0.307 g, 12.8 mmoles) in THF (91 ml). The mixture was stirred at room temperature until H2 was no
longer evolved (10 minutes). Then, a solution of methyl rac-(R)-3-(phenylselenyl)-3-(methoxycarbonyl)-2-oxopentade-
canoate (5.63 g, 11.64 mmoles) in THF (8 ml) was added. The resulting mixture was stirred at room temperature for 24
hours. After that time, the solvent was removed under reduced pressure. The product was purified by a chromatographic
column (hexane/AcOEt, 15:1), obtaining (4.53 g, yield 72%) a mixture in a 5:2 ratio of methyl rac-(E,R)-2-(phenylselenyl)-
3,4-bis(methoxycarbonyl)-3-hexadecenoate (trans, 51%) and methyl (Z)-3,4-bis(methoxycarbonyl)-3-hexadecenoate
(cis, 21%), as a brown oil.
IR (NaCl): v 2925, 2854, 1733, 1632, 1577, 1458, 1435, 1313, 1268, 1199, 1158, 1125, 1075, 1001, 742, 693 cm-1.
1H-NMR (200 MHz, CDCl3). δ 7.39 (5H, m, Ar-H trans), 4.64 (1H, s, H-2 trans), 3.71 (3H, s, -OCH3 cis), 3.69 (3H, s,
-OCH3 trans), 3.68 (3H, s, -OCH3 trans), 3.67 (3H, s, - OCH3 trans), 3.65 (3H, s, -OCH3 cis), 3.61 (3H, s, -OCH3 cis),
3.33 (2H, s, H-2 cis), 2.23 (2H, m, H-5 cis), 1.83 (2H, m, H-5 trans), 1.13 (20H, m, -CH2- trans, cis), 1.17 (20H, m,
-CH2- trans, cis), 0.79 (3H, m, -CH3 trans), 0.76 (3H, m, -CH3 cis).
13C-NMR (50 MHz, CDCl3). δ 169.9, 169.0, 166.2, 146.1, 143.1, 136.1, 129.8, 129.0, 128.8, 125.2, 52.9, 52.2, 52.1,
43.2, 33.5, 31.7, 31.2, 30.4, 29.4, 29.4, 29.3, 29.1, 29.1, 29.0, 27.3, 22.5, 20.8, 14.0, 13.9.
LRMS(EI): m/z 540(M++1,6), 508(33), 383(12), 351(100), 291(8), 197(25).
Example 9
Preparation of methyl rac-(Z,R)-4-hydroxy-3,4-bis(methoxycarbonyl)-2-hexadecenoate
[0095]
[0096] An aqueous solution of 33% H2O2 (5.99 ml) was added to a solution of methyl rac-(E,R)-2-(phenylselenyl)-3,4-
bis(methoxycarbonyl)-3-hexadecenoate (trans) (4.53 g, 8.39 mmoles) and pyridine (1.32 g, 16.79 mmoles) in CH2Cl2
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(70 ml). The mixture was stirred at room temperature for 24 hours. After that time, the solvent was removed under
reduced pressure. The residue was dissolved in AcOEt (30 ml), and H2O (30 ml) was added. The phases were separated,
and the aqueous phase was extracted with AcOEt (3  10 ml). The organic phase was dried with anhydrous Na2SO4,
filtered and the solvent was removed under reduced pressure. The product was purified by a chromatographic column
(hexane/AcOEt, 10:1), obtaining (2.2 g, yield 65%) methyl rac-(Z,R)-4-hydroxy-3,4-bis(methoxycarbonyl)-2-hexade-
cenoate as a colorless oil.
IR (NaCl): v 3494, 2925, 2854, 1733, 1646, 1436, 1349, 1256, 1199, 1168, 1019 cm-1.
1H-NMR (300 MHz, CDCl3). δ 6.26 (1H, s, H-2), 3.80 (3H, s, -OCH3), 3.80 (3H, s, - OCH3), 3.71 (3H, s, -OCH3), 3.67
(1H, s, -OH), 1.91 (2H, m, -CH2-), 2.43 (2H, m, - CH2-), 1.22 (18H, m, -CH2-), 0.85 (3H, t, J = 6.8 Hz, -CH3).
13C-NMR (75 MHz, CDCl3). δ 173.0, 166.8, 164.9, 151.0, 120.3, 77.7, 53.6, 52.4, 52.0, 37.5, 31.8, 31.5, 29.5, 29.5,
29.4, 29.3, 29.3, 29.2, 23.1, 22.6, 14.0.
LRMS(EI): m/z 401(M++1,3), 383(1), 369(8), 341(28), 309(100), 249(18), 197(18).
E.A. (C21H36O7): Found: C, 63.00, H, 9.00; Calculated: C, 62.98, H, 9.06.
Example 10
Preparation of rac-(3R,4S,5S)-3,4-dihydroxy-3-dodecyl-4,5-bis(methoxycarbonyl)tetrahydro-2-furanone (IV)
[0097]
[0098] NMO (1.21 g, 9.99 mmoles) and OsO4 (2.5% in tert-BuOH, 0.019 g, 0.075 mmoles) were added to a solution
of methyl rac-(Z,R)-4-hydroxy-3,4-bis(methoxycarbonyl)-2-hexadecenoate (1 g, 2.50 mmoles) in a 5:1 acetone/H2O
mixture (10.2 ml). The mixture was stirred at room temperature for 2 days. After that time, an aqueous solution of 10%
Na2S2O3 (0.2 ml) was added. The mixture was filtered through silica gel with MeOH and the solvent was removed under
reduced pressure. The product was purified by a chromatographic column (hexane/AcOEt, 3:1), obtaining (0.670 g, yield
67%) rac-(3R,4S,5S)-3,4-dihydroxy-3-dodecyl-4,5-bis(methoxycarbonyl)tetrahydro-2-furanone (IV) as a white solid.
m.p.: 74-76°C
IR (KBr): v 3400, 3339, 2956, 2918, 2851, 1785, 1775, 1714, 1467, 1445, 1364, 1307, 1226, 1155, 1133, 1061 cm-1.
1H-NMR (200 MHz, CDCl3). δ 5.21 (1H, s, H-5), 3.87 (3H, s, -OCH3), 3.78 (3H, s, - OCH3), 3.56 (1H, Sbroad, -OH), 2.90
(1H, Sbroad, -OH), 1.80 (2H, m, H-6), 1.21 (20H, Sbroad, -CH2-), 0.83 (3H, m, -CH3).
1H-NMR (300 MHz, DMSO-d6). δ 6.74 (1H, s, -OH), 6.41 (1H, s, -OH), 5.50 (1H, s, H-5), 3.72 (3H, s, -OCH3), 3.65 (3H,
s, -OCH3), 1.68 (2H, m, H-6), 1.39 (2H, m, H-7), 1.23 (18H, Sbroad, -CH2-), 0.84 (3H, m, -CH3).
13C-NMR (50 MHz, CDCl3). δ 173.9, 170.6, 166.4, 81.0, 78.5, 54.0, 52.7, 31.7, 29.6, 29.5, 29.4, 29.2, 29.2, 22.5, 21.5, 13.9.
LRMS(EI): m/z 402(M+, 0), 315(2), 285(2), 234(2), 216(0), 197(11), 160(30), 101 (100).
E.A. (C20H34O8): Found: C, 59.70, H, 8.50; Calculated: C, 59.68, H, 8.51.
Example 11
Reaction of rac-(3R,4S,5S)-3,4-dihydroxy-3-dodecyl-4,5-bis(methoxycarbonyl)tetrahydro-2-furanone with LiOH/HCl
[0099]
[0100] An aqueous solution of 1N LiOH (0.104 g, 2.48 mmoles, 2.5 ml) was added to a solution of rac-(3R,4S,5S)-
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3,4-dihydroxy-3-dodecyl-4,5-bis(methoxycarbonyl)tetrahydro-2-furanone (IV) (0.050 g, 0.12 mmoles) in THF (5 ml). The
mixture was stirred at room temperature for 2 hours. After that time, the phases were separated. The aqueous phase
was washed with AcOEt (2  2 ml), treated with an aqueous solution of 10% HCl (until acidic pH) and extracted with
AcOEt (3  3 ml). The extracts were dried with anhydrous Na2SO4, filtered and the solvent was removed under reduced
pressure, obtaining (0.026 g, yield 56%) a mixture in a 1:1 ratio of rac-(3R,4S,5S)-3,4-dihydroxy-3-dodecyl-4,5-dicar-
boxytetrahydro-2-furanone (Cinatrin C3) and rac-(3S,4S,5R)-3,4-dihydroxy-5-dodecyl-4,5-dicarboxytetrahydro-2-
furanone (Cinatrin C1) as a white solid.
1H-NMR (300 MHz, CD3OD). δ 5.39 (1H, s, H-5, Cinatrin C3), 4.70 (1H, s, H-3 Cinatrin C1), 2.16 (1H, m, H-6 Cinatrin
C1), 1.82 (2H, m, H-6 Cinatrin C3), 1.68 (1H, m, H-6 Cinatrin C1), 1.50 (1H, m, H-7 Cinatrin C1), 1.46 (2H, m, H-7
Cinatrin C3), 1.36 (1H, m, H-7 Cinatrin C1), 1.29 (18H, Sbroad, -CH2- Cinatrin C3, Cinatrin C1), 0.88 (3H, m, -CH3
Cinatrin C3, Cinatrin C1).
13C-NMR (75 MHz, CD3OD). Cinatrin C3: δ 176.8, 172.6, 170.3, 82.1, 81.2, 80.8, 33.2, 32.1, 31.4, 30.8, 30.7, 30.5,
30.4, 23.6, 22.6, 14.5; Cinatrin C1: δ 175.8, 172.0, 88.6, 85.7, 74.8, 33.4, 32.3, 31.6, 30.5, 30.4, 30.3, 30.1, 23.8, 22.4,
14.3.
LRMS(EI): m/z 374(M+, 0), 355(1), 331(1), 297(3), 267(3), 249(3), 207(5), 197(93), 57(100).
Claims
1. A process for obtaining a compound of formula (II)
wherein
R2 is aC10-C15 alkyl group; and
R3 and R5 are independently selected from a substituted or unsubstituted C1-C20 alkyl group;
its stereoisomers, or mixtures thereof;
which process comprises dihydroxylating the double bond of a compound of formula (III)
wherein
R2, R3 and R5 have the previously mentioned meaning; and
R1 is selected from a substituted or unsubstituted C1-C20 alkyl group.
2. The process according to claim 1, wherein the compound of formula (III) is a compound of formula (IIIa), or its
enantiomers
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wherein R1, R2, R3 and R5 are as defined in claim 1;
and the compound of formula (II) obtained is a compound of formula (IIa), or its enantiomers
wherein R2, R3 and R5 are as defined in claim 1.
3. The process according to any of the previous claims, wherein the dihydroxylation is performed in the presence of
osmium tetroxide/N-methylmorpholine-N-oxide or potassium permanganate.
4. A compound of formula (III)
wherein
R1, R3 and R5 are independently selected from a substituted or unsubstituted C1-C20 alkyl group; and
R2 is selected from a C10-C15 alkyl group;
its stereoisomers, or mixtures thereof.
5. A process for the synthesis of a compound of formula (III)
EP 2 287 157 A1
21
5
10
15
20
25
30
35
40
45
50
55
wherein
R1, R3 and R5 are independently selected from a substituted or unsubstituted C1-C20 alkyl group; and
R2 is a C10-C15 alkyl group;
its stereoisomers, or mixtures thereof;
which comprises
(a) reacting a compound of formula (V)
wherein
R1, R2 and R3 are as defined above;
in the presence of a compound of formula (XII)
wherein
R5 is as defined above;
or
(b) oxidizing with a peroxide or with sodium periodate a compound of formula (VI)
wherein
R1, R2, R3 and R5 are as defined above; and
R6 is selected from the group formed by C1-C3 alkyl and phenyl.
6. The process according to claim 5, wherein the compound of formula (VI) is prepared by
(i) reacting in the presence of a base a compound of formula (VII)
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wherein
R1, R2 and R3 are defined as in claim 5;
with a compound of formula (XV)
R6SeX (XV)
wherein
R6 is defined as in claim 5; and
X is a halogen selected from Cl and Br;
to obtain a compound of formula (XIII)
wherein
R1, R2, R3 and R6 are defined as in claim 5; and
(ii) reacting said compound of formula (XIII) in the presence of a base with a phosphonate of formula (XIV)
wherein
R5 is defined as in claim 5; and
R7 is a C1-C3 alkyl group.
7. The process according to claim 5, wherein the compound of formula (V) is prepared by
(i) reacting a compound of formula (VII)
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wherein
R1, R2 and R3 are defined as in claim 5;
with a trialkylsilyl halide or with a trialkylsilyl triflate in the presence of a base to obtain a compound of formula (X)
wherein
R1, R2 and R3 are defined as in claim 5; and
R4 is a trialkylsilyl group;
(ii) reacting said compound of formula (X) with an epoxidizing agent to obtain a compound of formula (XI)
wherein
R1, R2 and R3 are defined as in claim 5; and
R4 is as defined above; and
(iii) reacting said compound of formula (XI) with a compound capable of generating fluoride ions.
8. The process according to claim 7, wherein said epoxidizing agent is selected from the group formed by 3-chloroper-
oxybenzoic acid, 2-sulfonyloxaziridines and the HOF·CH3CN complex.
9. The process according to claim 7, wherein the epoxidation is asymmetric.
10. The process according to any of claims 6-9, wherein the compound of formula (VII) is prepared by reacting in the
presence of a base a compound of formula (VIII)
EP 2 287 157 A1
24
5
10
15
20
25
30
35
40
45
50
55
wherein
R1 and R2 are defined as in claim 6;
with an oxalic acid diester of formula (IX)
wherein
R3 is defined as in claim 6.
11. A compound of formula (V)
wherein
R1 and R3 are independently selected from a substituted or unsubstituted C1-C20 alkyl group; and
R2 is selected from a C10-C15 alkyl group;
its stereoisomers, or mixtures thereof.
12. A compound of formula (XI)
wherein
R1 and R3 are independently selected from a substituted or unsubstituted C1-C20 alkyl group;
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R2 is selected from a C10-C15 alkyl group; and
R4 is a trialkylsilyl group;
its stereoisomers, or mixtures thereof.
13. A compound of formula (X)
wherein
R1 and R3 are independently selected from a substituted or unsubstituted C1-C20 alkyl group;
R2 is selected from a C10-C15 alkyl group; and
R4 is a trialkylsilyl group
its stereoisomers or mixtures thereof.
14. A compound of formula (VI)
wherein
R1, R3 and R5 are independently selected from a substituted or unsubstituted C1-C20 alkyl group;
R2 is selected from a C10-C15 alkyl group; and
R6 is selected from the group formed by C1-C3 alkyl and phenyl;
its stereoisomers, or mixtures thereof.
15. A compound of formula (XIII)
wherein
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R1 and R3 are independently selected from a substituted or unsubstituted C1-C20 alkyl group;
R2 is selected from a C10-C15 alkyl group; and
R6 is selected from the group formed by C1-C3 alkyl and phenyl;
its stereoisomers, or mixtures thereof.
16. A compound of formula (VII)
wherein
R1 and R3 are independently selected from a substituted or unsubstituted C1-C20 alkyl group; and
R2 is selected from a C10-C15 alkyl group;
its stereoisomers, or mixtures thereof.
17. The compound according to any one of claims 11 to 16, wherein R1 = R3 = Me and R2 = n-dodecyl.
18. A process for preparing compounds of formula (Ia) and/or (Ib)
wherein
R2 is a C10-C15 alkyl group;
their stereoisomers, or mixtures thereof, or mixtures of the compounds of formula (Ia) and (Ib) or mixtures of their
stereoisomers,
which comprises
(i) dihydroxylating the double bond of a compound of formula (III)
wherein
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R1 is selected from a substituted or unsubstituted C1-C20 alkyl group;
R2 is as defined above; and
R3 and R5 are independently selected from a substituted or unsubstituted C1-C20 alkyl group;
to obtain a compound of formula (II)
wherein
R2, R3 and R5 are as defined above;
its stereoisomers, or mixtures thereof;
(ii) hydrolyzing said compound of formula (II) in the presence of an alkali or alkaline earth metal hydroxide, or
of an alkali or alkaline earth metal carbonate; and
(iii) acidifying the reaction medium;
wherein the R3 and R5 groups are labile under the basic conditions of step (ii).
19. The process according to claim 18, for preparing compounds of formula (Ia’) and (Ib’), or their enantiomers
wherein
R2 is as defined in claim 18;
the compound of formula (III) is a compound of formula (IIIa), or its enantiomers
wherein R1, R2, R3 and R5 are as defined in claim 18; and
the compound of formula (II) is a compound of formula (IIa), or its enantiomers
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wherein R2, R3 and R5 are as defined in the claim 18.
20. A process for preparing a compound of formula (Ia)
wherein
R2 is a C10-C15 alkyl group;
its stereoisomers, or mixtures thereof,
which comprises
(i) dihydroxylating the double bond of a compound of formula (III)
wherein
R1 is selected from a substituted or unsubstituted C1-C20 alkyl group;
R2 is as defined above; and
R3 and R5 are independently selected from a substituted or unsubstituted C1-C20 alkyl group;
to obtain a compound of formula (II)
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wherein
R2, R3 and R5 are as defined above;
its stereoisomers, or mixtures thereof; and
(ii) transforming under non-basic conditions the carboxy ester groups of the lactone ring of the compound of
formula (II) to obtain the corresponding carboxy acid groups.
21. A compound of formula (II)
wherein
R2 is selected from a C10-C15 s alkyl group;
R3 and R5 are independently selected from a substituted or unsubstituted C1-C20 alkyl group;
its stereoisomers, especially enantiomers, or mixtures thereof;
with the proviso that the compound of formula (II) is not
22. Use of a compound of formula (II) as defined in claim 21, for the synthesis of compounds of formula (Ia) and/or (Ib),
their stereoisomers, or mixtures thereof, as well as mixtures of compounds of formula (Ia) and (Ib) or mixtures of
their stereoisomers.
23. Use of at least one compound of formula (III), (V), (VI), (VII), (X), (XI) and (XIII) as defined in the previous claims
for the synthesis of compounds of formula (Ia) and/or (Ib), their stereoisomers, or mixtures thereof, as well as
mixtures of compounds of formula (Ia) and (Ib) or mixtures of their stereoisomers.
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